tbuckley/cabot-search huggingface dataset:
TMOD-27. AUTOPSY DERIVED ORTHOTOPIC XENOGRAFT (ADOX) MOUSE MODELS FOR TERMINAL PEDIATRIC BRAIN TUMORS
Authors: Lin Qi, Patricia Baxter, Mari Kogiso, Yuchen Du, Holly Lindsay, Zhigang Liu, Jack Su, Adekunle Adesina, Andrew Walter, Jeffrey Murray, Rene McNall-Knapp, Javad Nazarian, D. Will Parsons, Murali Chintagumpala, Susan Blaney, Xiao-Nan Li
Journal: Neuro-Oncology (2016)

Brain tumors are the leading cause of cancer related death in children. Autopsy is frequently the only chance to obtain tumor tissues and it remains unknown if autopsied tumors can be used for model development. Thus we collected 30 autopsied brain tumors, including 15 diffuse intrinsic pontine gliomas (DIPG), 8 glioblastomas (GBM), 4 medulloblastomas (MB), 2 ependymoma and 1 atypical teratoid/rhabdoid tumor (ATRT), and made the following discoveries. i) A small fraction of tumor cells exhibited strong survival capacity and remained viable, ranging from 0.5%-40% in tumors harvested 5-72 hrs after patients’ death. Cell viability did not appear to be strictly correlated with the length of autopsy time. ii) While many autopsied tumor cells appear to have stayed alive for short terms in culture, only one pair of permanent GBM lines were established. iii) Direct implantation of tumor cells into matched locations in the brains of SCID mice led to the formation of xenograft tumors in 17 of 22 tumors. Detailed characterization confirmed their replication of histopathological features and genetic/genomic abnormalities of the patient tumors. iv) To identify the cellular origin of surviving patient tumor cells that propagated ADOX model formation, time course analysis of putative cancer stem cells was performed. CD57+ tumor cells were found to be the most abundant subpopulations in the autopsied tumors, and their fractions increased in the ADOX tumors during serial subtransplantations. Additionally, CD57+ cells alone were able to form orthotopic xenografts, establishing their role as cancer stem cells. In conclusion, we have demonstrated that a fraction of tumor cells can survive the lengthy period of postmortem anoxia/starvation and regain tumorigenic capabilities in mouse brains; and identified CD57 as a new marker of the therapy-resistant cells. This novel panel of ADOX models should facilitate biological studies and preclinical therapy of pediatric brain tumors.
OP0141 1,25(OH)2D3 modulates gene expression involved in cytokine production, proliferation, survival and migration of TH17 cells from patients with rheumatoid arthritis
Authors: W. Dankers, J.P. van Hamburg, P.S. Asmawidjaja, N. Davelaar, K. Wen, A.M.C. Mus, E.M. Colin, J.P.T.M. van Leeuwen, J.M.W. Hazes, E. Lubberts
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Vitamin D has suppressive effects on autoimmune diseases, such as rheumatoid arthritis (RA). Within these diseases, T-helper-17 (Th17) cells have been implicated toplay a crucial role in the development and progression of chronic inflammation. Recently, we have found that the active vitamin D compound, 1,25(OH)<sub>2</sub>D<sub>3</sub>, has direct suppressive effects on both human and mouse Th17 cytokine expression and activity. <h3>Objectives</h3> Using gene-expression profiling, we aim to identify molecular targets of 1,25(OH)<sub>2</sub>D<sub>3</sub> signaling underlying the suppressive action of 1,25(OH)<sub>2</sub>D<sub>3</sub> in Th17 cells from patients with RA. <h3>Methods</h3> Primary Th17 cells were sorted from peripheral blood of treatment naïve patients with early RA and cultured with or without 1,25(OH)<sub>2</sub>D<sub>3</sub>. From these cultures gene-expression profiles were generated. Expression of genes of interest was confirmed by Q-PCR and/or specific ELISA. <h3>Results</h3> In the presence of 1,25(OH)<sub>2</sub>D<sub>3</sub>, protein expression of Th17 associated cytokines IL-17A and IL-22 was inhibited, while in contrast the anti-inflammatory cytokine IL-10 was induced. These findings were supported by the gene-expression profiles from these cultures. Furthermore, 1,25(OH)<sub>2</sub>D<sub>3</sub> inhibited transcription of the cytokine receptors IL-23R and IL-7R, which are involved in Th17 survival and proliferation. Chemokines CCL20 and CXCL10 were down-regulated and chemokine receptors CCR2, CXCR6, CXCR3 and CCR10 were up-regulated. Importantly, Rorgt, which is critically involved in Th17 differentiation and function and the cell-size regulator and oncogene, c-Myc were down-regulated by 1,25(OH)<sub>2</sub>D<sub>3</sub>. <h3>Conclusions</h3> From these findings, we concluded that 1,25(OH)<sub>2</sub>D<sub>3</sub> modulates the expression of genes involved in cytokine production, proliferation, survival and migration of Th17 cells. These data indicate that 1,25(OH)<sub>2</sub>D<sub>3</sub> not only suppresses Th17 cell activity but also regulates migration of these cells to sites of tissue inflammation in RA. <h3>Disclosure of Interest</h3> None Declared
Brief Travel to Subtropical Areas Imports Flu, Researchers Say
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Divergent trends in childhood drowning rates, 1971 through 1988
Authors: R. A. Brenner
Journal: JAMA (1994)

<h3>Objective.</h3> —To examine national age-, race-, and sex-specific trends in unintentional drowning rates among US children aged 0 through 19 years. <h3>Design.</h3> —National mortality data published by the National Center for Health Statistics and population data from the US Bureau of the Census were used in calculating age-, race-, and sex-specific drowning rates for 1971 through 1988. Time trends were analyzed using Poisson regression techniques. <h3>Setting.</h3> —United States, 1971 through 1988. <h3>Main Outcome Measure.</h3> —Rates of death due to unintentional, non-boatrelated drowning. <h3>Results.</h3> —From 1971 through 1988, there were 45680 unintentional, non—boatrelated drowning deaths among 0- through 19-year-olds in the United States. Drowning rates declined sharply in older children (-5.8% per year in 10- through 14-year-olds and —5.4% per year in 15-through 19-year-olds), declined only slightly in toddlers (-1.6% per year in 1- and 2-year-olds), and actually increased in infants (+1.6% per year in those children younger than 1 year). <h3>Conclusion.</h3> —Drowning rates in toddlers have changed little over time despite the availability of effective prevention strategies such as pool fencing. In older children, drowning rates have declined dramatically despite the lack of clear preventive initiatives. Prevention interventions targeted specifically at the infant and toddler age groups should receive priority. (<i>JAMA</i>. 1994;271:1606-1608)
THE RESPONSIBILITY OF THE MEDICAL SCHOOL FOR CONTRACT PRACTICE AND OTHER EVILS.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ophthalmia Neonatorum.
Authors: John M. Batten
Journal: JAMA (1897)

Pittsburgh, Pa., March 8, 1897. <h3>To the Editor:</h3> —Recently I had a case of ophthalmia neonatorum in which only the left eye was affected. This has never occurred in my practice before. The disease has always affected both eyes and this is the reason I report the case. My treatment for this disease is first to wash the eyes out well with warm water by means of a small wad of medicated cotton followed by a wash of muriat. ammon. gr. vi, bichlorid. hydrarg. gr. j. aquæ dest. [unk]vi. M. Sig. A teaspoonful in a teaspoonful of boiling water, immediately followed by a 20 grain solution of argentum nitrate and then by a saturated solution of chlorid of sodium. This is repeated every three or four hours. Once a day or once in two days I apply a drop or two of the solution of sulphate of atropia 1 grain
NUCLEAR MEDICINE APPROACHES: ANALYSIS OF ORGAN-SPECIFIC BLOOD POOL CHANGES IN RESPONSE TO VASOACTIVE DRUGS FOR HEPATOCYTE TRANSPLANTATION
Authors: M. V. Camaya, P. Rajvanshi, K. K. Bhargava, C. J. Palestro, S. Gupta
Journal: Clinical Nuclear Medicine (1996)

Camaya, M.; Rajvanshi, P.*; Bhargava, K. K.; Palestro, C. J.; Gupta, S.*Editor(s): Blend, Michael; Haseman, Michael Author Information
Pulmonary arterial hypertension in patients treated with interferon
Authors: Laurent Savale, Caroline Sattler, Sven Günther, David Montani, Marie-Camille Chaumais, Swanny Perrin, Xavier Jaïs, Andrei Seferian, Roland Jovan, Sophie Bulifon, Florence Parent, Gérald Simonneau, Marc Humbert, Olivier Sitbon
Journal: European Respiratory Journal (2014)

Isolated cases of pulmonary arterial hypertension (PAH) in patients treated with interferon (IFN) α or β have been reported in the literature. The aim of this study was to describe all consecutive cases of PAH patients with a history of IFN exposure identified in the French reference centre for severe pulmonary hypertension between 1998 and 2012. A total of 53 patients with PAH and a history of IFN therapy were identified. 48 patients had been treated with IFNα for chronic hepatitis C. Most of them had portal hypertension (85%) and 56% had HIV co-infection. Five additional patients had been treated with IFNβ for multiple sclerosis. The diagnosis of PAH was made within 3 years after IFN therapy in 66% of patients. Repeated haemodynamic assessment was available in 13 out of 16 patients exposed to IFN after the diagnosis of PAH. Increased pulmonary vascular resistance &gt;20% was observed in 11 out of 13 cases (median 43% increase; IQR 32–67%). In five of these patients, IFN withdrawal resulted in spontaneous haemodynamic improvement. This retrospective analysis suggests that IFN therapy may trigger PAH. However, most of these patients had other risk factors for PAH. A prospective case–control study is necessary to definitively establish a link between IFN exposure and PAH.
Deep Brain Stimulation for Patients With Advanced Parkinson Disease—Reply
Authors: Frances M. Weaver
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Journal: Circulation (2013)

In the article by Morillo, "Infection With Trypanosoma cruzi and Progression to Cardiomyopathy: What is the Evidence and Is the Tide Finally Turning," which was published in the March 12, 2013 issue of the journal (Circulation.2013;127:1095-1097), an error occurred.On page 1096 in the first full paragraph, "…26% of the T cruzi-seronegative subjects…" should have read, "…26% of the T cruzi-seropositive subjects…".The error has been corrected in the current online version of the article.The authors regret the error.
Upper GI/basic
Authors: N Mcdougall, B Johnston, F Kee, J Collins, R Mcfarland, R Watson, A Lanas, J Blas, J Ortego, R Sousa
Journal: Gut (1994)

Aims: To study the long term effects of oesophagitis and its cost to the com- munity.Methods: Eighty-eight patients in whom grade I-l1l oesophagitis (modified Savary-Miller class.)was diagnosed in one centre 10 to 12 years ago were traced and invited to complete a detailed questionnaire on symptoms and drug therapy.Eleven patients had died (none due to oesophageal disease), 32 did not respond and 45 replied (22 male).Results: Forty-five patients (mean age 56.9 yrs, range 28 to 81 yrs) were followed-up after a mean of 138 months (121-153 months).Thirteen (29%) had grade oesophagitis at initial endoscopy and 32 (71%) had grade 11- 111.Heartburn occurred at least monthly in 30 (67%) patients of which 15 (33%) had daily symptoms.Severity of symptoms was considered minor in 21 (47%), moderate/major in 22 (49%) or unbearable in 2 (4%).Twenty-one (47%) said their condition was better now than 10 years ago.Twenty-three (51 %) were currently on maintenance acid suppression ± antacids, and a fur- ther 1 1 (24%) were on antacids alone at least weekly.Only 2 patients were not on any anti-reflux medication.No patient had undergone anti-reflux surgery or had developed an endoscopically proven stricture, although 4 (9%) had daily dysphagia with liquids and solids.No significant differences were found on comparing the symptoms and drug consumption of those with grade oesophagitis to those with grades 11 or 1II.A total of 8813 weeks of standard dosage of either H2-receptor antagonists or proton pump inhibitors had been taken over the review period -an average of 192 weeks of therapy per patient.Based on today's prices this approximates to a total cost of £62,710, or £121 per patient per year for acid suppression therapy alone.Conclusions: Oesophagitis contributes significantly to morbidity in the community 10 years after initial diagnosis.Grade of oesophagitis did not in- fluence the degree of symptoms or amount of therapy taken.
Obstetrics for Nurses.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Australian &amp;amp; New Zealand J Surg, Melbourne
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Disposable skin hook
Authors: W. S. Brothers
Journal: JAMA (1968)

<h3>To the Editor:—</h3> Precordial stethoscopic monitoring is a valuable adjunct in pediatric anesthesia management; however, maintaining the usual style chest piece in proper contact with the chest wall during surgical gymnastics (without the dangers of dislodgement or of producing an area of pressure ischemia to the underlying skin) has always been a problem. With the advent of the stethoscope transducer, I have been gratified with the results of the following refinement of this technique, ie, apply a coat of compound tincture of benzoin and allow it to dry for a few moments; then attach a pediatricsize stethoscope transducer over the left nipple area so both respiratory and cardiac sounds are plainly audible (Fig 1). The stethoscope transducer will adhere tightly to the skin without danger of pressure damage. As further insurance against movement of the stethoscope transducer, surgical tape can be used to reinforce the application (Fig 2). The intimate
Publication of CDC Surveillance Summaries
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vitamin K
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Monthly Problem in Cutaneous Medicine
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal